HOLIDAY SHIPPING UPDATE: All delivery request will not be processed on Monday, February 17, 2020 as it is BC Family Day. Regular delivery schedule will resume the next business day.
FGFR4 (N535K), Active(F07-12G)

FGFR4 (N535K), Active(F07-12G)

  • $226.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant human FGFR4 (N535K) (460-end) was expressed by baculovirus in Sf9 cells using an N-terminal GST tag.

Species :Human

Tag :GST tag

Expression System:Sf9 insect cells using baculovirus

Sequence :460-end (N535K)

Genbank Number :NM_002011

Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications :Kinase Assay

Molecular Weight :~65 kDa

Gene Aliases :TKF, JTK2, CD334, MGC20292

Scientific Background :FGFR4 is a member of the fibroblast growth factor receptor family which play a role in mitogenesis and differentiation (1). FGFR4 preferentially binds acidic fibroblast growth factor and is overexpressed in gynecological tumor samples, suggesting a role in breast and ovarian tumorigenesis. FGFR4 gene expression is up-regulated in doxorubicin-treated, apoptosis-resistant cancer cell clones (2). Ectopic expression of FGFR4 in cancer cells leads to reduced apoptosis sensitivity on treatment with doxorubicin or cyclophosphamide, whereas knockdown of endogenous FGFR4 expression in breast cancer cell lines has the opposite effect.

References :
1. Holtrich, U.;: Two additional protein-tyrosine kinases expressed in human lung: fourth member of the fibroblast growth factor receptor family and an intracellular protein-tyrosine kinase. Proc. Nat. Acad. Sci. 88: 10411-10415, 1991.

2. Roidl, A. et al: Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res. 2009 Mar 15;15(6):2268-66.

Product Sheets (By Lot #) :

T1017-1.pdf

Research Areas :AKT/PKB Pathway, Cancer, ERK/MAPK Pathway, Invasion/Metastasis, Receptor Tyrosine Kinases, Cancer, AKT/PKB Pathway, ERK/MAPK Pathway, Angiogenesis, Receptor Tyrosine Kinases